Frontlight ResearchEarly access
Active, not recruitingPhase 2
Sildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries
Key facts
- Who runs it
- The University of Texas Medical Branch, Galveston
- Where
- College Station and Galveston, United StatesSee the 2 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 24 people, planned
- Started
- 7 Jul 2021
- Expected to end
- 1 Dec 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- Sildenafil Citrate
- Placebo
- Record updated
- 9 September 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Adults with spinal cord injury (SCI), 18-75 years of age, at the time of consent
- Have urinary incontinence (UI), with at least 3 leakage episodes/week
- Have urodynamics assessment on file with their provider in past 3 years. If no historical data on file, subject may complete prior to study visit 1
- Willing and able to comply with study procedures
- Willing and able to provide written informed consent
Who cannot take part
- Use of systemic nitrates, anabolic steroids, corticosteroids, or long acting PDE5 inhibitors in the past 1 month
- Use of short acting PDE5 inhibitors in the past 1 week
- Atonic bladder or high detrusor and high pelvic floor muscle pressure based on previous cystometrogram (CMG) (on file with their provider) that would place subjects at risk for kidney injury
- History of greater than 4 urinary tract infections per year
- Significant heart, liver, kidney, pulmonary, blood, autoimmune or peripheral vascular disease
- Active cancer
- HIV, Hepatitis B, or Hepatitis C
- Known allergic reaction to any agent under investigation or required by the protocol
- Any medical condition that, in the opinion of the investigator, would place the subject at increased risk for participation
- In phone prescreen, delighted or pleased with current quality of life due to urinary symptoms
- Indwelling catheter
- Multiple sclerosis
- Systolic blood pressure <90 or >170, diastolic blood pressure <50 or >110 after repeated evaluation with proper cuff. This range is the acceptable range stated in the prescribing information for sildenafil (>90/50 and <170/110)
- Use of alpha blockers, anticholinergic agents, bethanechol, or other UI treatment within the past 2 weeks ( 3 weeks for long acting muscarinic receptor antagonists)
- Females who are pregnant or lactating
Where in United States
- Texas A&M UniversityCollege Station, United States
- University of Texas Medical BranchGalveston, United States
About the trial
What the trial wants to find out
The goal of this study is to determine whether administration of sildenafil will decrease urine leakage in patients with spinal cord injuries.
The 2 groups in the trial
- Sildenafil 20mg TID then Placebo TIDTreatment being tested
Subjects will be administered Sildenafil 20mg TID for 4 weeks. There will be a 2 week washout period then subjects will be administered Placebo (lactose) TID for 4 weeks.
Treatment: Sildenafil Citrate and Placebo
- Placebo TID then Sildenafil 20mg TIDTreatment being tested
Subjects will be administered Placebo (lactose) TID for 4 week. There will be a 2 week washout period and then subjects will be administered Sildenafil 20mg TID for 4 weeks.
Treatment: Sildenafil Citrate and Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 9 September 2026